


GP 1633 #8  
5-17-00

		Complete if Known	
		Application Number	09/258,217
		Filing Date	26 February 1999
		First Named Inventor	Mark T. KEATING et al.
		Group Art Unit	1633
		Examiner Name	Shin-Lin Chen
Total Amount of Payment	(\$55.00)	Attorney Docket Number	2323-127

# METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck

☐ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Charge for the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. ☒ Payment Enclosed: Check

# FEE CALCULATION

## 1. FILING FEE

Fee Description	Fee Code	Fee Paid
<input type="checkbox"/> Utility Filing Fee	201	345
<input type="checkbox"/> Design Filing Fee	206	155
<input type="checkbox"/> Plant Filing Fee	207	240
<input type="checkbox"/> Reissue Filing Fee	208	345
<input type="checkbox"/> Provisional Filing Fee	214	75

**SUBTOTAL** \$

## 2. CLAIMS

	Total Claims	Fee from Extra	below	Fee Paid
Independent Claims	- 20 =	x	\$ 9	=
Multiple Dependent Claims	- 3 =	x	39	=
		+	130	=

**SUBTOTAL** \$

# FEE CALCULATION (continued)

## 3. ADDITIONAL FEES


Fee Description	Fee Code	Fee Paid
<input type="checkbox"/> Surcharge - late filing fee or oath	205	65
<input type="checkbox"/> Surcharge - late provisional filing fee or cover sheet	227	25
<input type="checkbox"/> Non-English specification	139	130
<input type="checkbox"/> For filing a request for reexamination	147	2,520
<input type="checkbox"/> Requesting publication of SIR prior to Examiner action	112	920
<input type="checkbox"/> Requesting publication of SIR after Examiner action	113	1,840*
<input checked="" type="checkbox"/> Extension for reply within first month	215	55
<input type="checkbox"/> Extension for reply within second month	216	190
<input type="checkbox"/> Extension for reply within third month	217	435
<input type="checkbox"/> Extension for reply within fourth month	218	680
<input type="checkbox"/> Extension for reply within fifth month	228	925
<input type="checkbox"/> Notice of Appeal	219	150
<input type="checkbox"/> Filing a brief in support of an appeal	220	150
<input type="checkbox"/> Request for Oral Hearing	221	130
<input type="checkbox"/> Petition to institute a public use proceeding	138	1,510
<input type="checkbox"/> Petition to revive -unavoidable	240	55
<input type="checkbox"/> Petition to revive - unintentional	241	605
<input type="checkbox"/> Utility issue fee (or reissue)	242	605
<input type="checkbox"/> Design issue fee	243	215
<input type="checkbox"/> Plant issue fee	244	290
<input type="checkbox"/> Petitions to the Commissioner	122	130
<input type="checkbox"/> Petitions related to provisional applications	123	50
<input type="checkbox"/> Submission of Information Disclosure Statement	126	240
<input type="checkbox"/> Recording each patent assignment per property (times number of properties)	581	40
<input type="checkbox"/> Filing a submission after final rejection (37 CFR 1.29(a))	246	345
<input type="checkbox"/> For each additional invention to be examined (37 CFR 1.129(b))	249	345

Other fee (specify)

☐

\* Reduced by Basic Filing Fee Paid

**SUBTOTAL** \$55.00

SUBMITTED BY		Complete (if applicable)	
NAME & REG. NUMBER	Stephen A. Saxe, Ph.D., Reg. No. 38,609		
SIGNATURE		DATE	11 May 2000
		DEPOSIT ACCOUNT USER ID	02-2135

RECEIVED  
 MAY 15 2000  
 TC 1600 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of

Mark T. KEATING et al.

Serial No.: 09/258,217

Filed: 26 February 1999

For: MICE WHICH ARE +/- OR  
-/- FOR THE ELASTIN  
GENE AS MODELS FOR  
VASCULAR DISEASE



Examiner: S-L. Chen

Group Art Unit: 1633

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed 2 February 2000, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 7-8 and 11-14.

Please amend the following claims:

a' -- 1. A mouse comprising a genome comprising a) one functional elastin gene and b) either one nonfunctional mouse elastin gene or no second elastin gene. --

a2 -- 3. A mouse cell comprising a genome comprising a) one functional elastin gene and b) one nonfunctional mouse elastin gene or no second elastin gene. --

sub D3  
93 -- 5. A method to screen for drug candidates useful for treating humans with SVAS, hypertension or atherosclerosis or useful for preventing atherosclerosis in humans, said method comprising administering said drugs to an ELN +/- [organism] mouse or human wherein drugs which inhibit occlusion of arteries in said organism are said drug candidates. --